Biotin-Linked Polyclonal Antibody to V-Erb B2 Erythroblastic Leukemia Viral Oncogene Homolog 3 (ErbB3)
| Code | Size | Price |
|---|
| LAC187Mu71-200ul | 200ul | £243.00 |
Quantity:
| LAC187Mu71-1ml | 1ml | £561.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Shipping:
4°C
Documents
Further Information
Alternative Names:
HER3; MDA-BF-1; C-ErbB3; LCCS2; ErbB3-S; P180-ErbB3; P45-SErbB3; P85-SErbB3; Receptor Tyrosine-Protein Kinase ErbB-3; Lethal Congenital Contracture Syndrome 2
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
V-Erb B2 Erythroblastic Leukemia Viral Oncogene Homolog 3
Source:
Antibody labeling
Usage:
Western blotting: 0.5-2ug/ml<br/>Immunocytochemistry in formalin fixed cells: 5-20ug/ml<br/>Immunohistochemistry in formalin fixed frozen section: 5-20ug/ml<br/>Immunohistochemistry in paraffin section: 5-20ug/ml<br/>Enzyme-linked Immunosorbent Assay: 0.05-2ug/ml<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Polyclonal Antibody to V-Erb B2 Erythroblastic Leukemia Viral Oncogene Homolog 3 (ErbB3) | PAC187Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||